'Real-life experience':recurrence rate at 3 years with Hexvix(®) photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study by Gallagher, Kevin M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
'Real-life experience'
Citation for published version:
Gallagher, KM, Gray, K, Anderson, CH, Lee, H, Stewart, S, Donat, R & Mariappan, P 2017, ''Real-life
experience': recurrence rate at 3 years with Hexvix(®) photodynamic diagnosis-assisted TURBT compared
with good quality white light TURBT in new NMIBC-a prospective controlled study' World journal of urology,
vol. 35, no. 12, 10.1007/s00345-017-2077-6, pp. 1871-1877. DOI: 10.1007/s00345-017-2077-6
Digital Object Identifier (DOI):
10.1007/s00345-017-2077-6
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
World journal of urology
Publisher Rights Statement:
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 09. May. 2019
Vol.:(0123456789) 
World J Urol 
DOI 10.1007/s00345-017-2077-6
ORIGINAL ARTICLE
‘Real‑life experience’: recurrence rate at 3 years with  Hexvix® 
photodynamic diagnosis‑assisted TURBT compared with good 
quality white light TURBT in new NMIBC—a prospective 
controlled study
Kevin M. Gallagher1 · Kayleigh Gray1 · Claire H. Anderson1 · Hannah Lee1 · 
Sarah Stewart1 · Roland Donat1 · Paramananthan Mariappan1 
Received: 4 May 2017 / Accepted: 31 July 2017 
© The Author(s) 2017. This article is an open access publication
1:1 based on demographic and pathological criteria. The 
primary outcome was overall and risk group-specific recur-
rence rate at 3 years.
Results Of 808 patients recruited, 345 had GQ-TURBT 
for NMIBC and were included. RR-3y was significantly less 
for GQ-PDD overall [RR-3y: GQ-PDD: 57/146 (39.0%), 
GQ-WL: 72/135 (53.3%) OR = 0.56 (0.35–0.90) p = 0.02] 
and on a 1:1 matched pair basis [RR GQ-PDD: 29/118 (24.6) 
vs. 59/118 (50.0) OR 0.33 (0.19–0.57) p < 0.001)]. Benefit 
was most marked in high-risk patients: RR-3y in high-risk 
patients treated with GQ-PDD was 25/48 (52.1%) vs. 28/35 
(80%) for GQ-WL [OR 0.27 (0.10–0.74) p = 0.01].
Conclusion When adopted for all new bladder tumour 
resections in routine practice, PDD appears to be associated 
with significantly reduced recurrence rates at 3 years in our 
“real life” experience, particularly in high-risk patients.
Keywords Bladder cancer · Non-muscle invasive bladder 
cancer (NMIBC) · Transurethral resection of bladder 
tumour (TURBT) · Photodynamic diagnosis (PDD)
Introduction
The long-term impact of photodynamic diagnosis (PDD)-
assisted trans-urethral resection of bladder tumour (TURBT) 
on non-muscle invasive bladder cancer (NMIBC) recurrence 
rates is not known. There are no prospective controlled stud-
ies that examine NMIBC recurrence rates after routine use 
of hexaminolevulinate (HAL)-PDD-TURBT. There are 
four randomised controlled clinical trials (RCTs) examin-
ing recurrence rates with HAL-PDD-TURBT vs. white light 
(WL) [1–7] but all have some limitations. Only one [6] has 
shown benefit of PDD beyond 1 year (24 months). There are 
three “real-life” observational studies of HAL-PDD all of 
Abstract 
Purpose To compare the recurrence rate at 3 years (RR-3y) 
for non-muscle invasive bladder cancer (NMIBC) between 
good quality (GQ) PDD-TURBT and GQWL-TURBT where 
PDD is used in routine practice for all new tumours.
Methods All new, consecutive, NMIBC that received 
“good quality” criteria first TURBT across a university 
hospital service were prospectively recruited to this study 
over a 4-year period. Data were prospectively collected on 
all WL-TURBTs performed in 2007/8 and compared with 
PDD-TURBT from 2009/10. Only resection meeting strict 
“good quality criteria” were included from each cohort to 
control for resection quality, then cases were further matched 
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which are within-patient analyses of detection rates and do 
not examine recurrence rates [8–10]. Prospective controlled 
studies of a new technique in routine use are required to aug-
ment RCTs since RCTs may not represent what happens in 
the real-life setting [11–13].
The only RCT with follow-up beyond 2 years did not 
show benefit of PDD [3]. This and all but one [7] other trial 
included new and recurrent tumours. No trial had resection 
quality standardization and only 2/4 gave any mitomycin 
C [3]. We know that the quality of resection is a critical 
determinant of NMIBC recurrence [14, 15] and mitomycin 
C is proven to significantly reduce recurrence rates [16]. 
Thus, in addition to the need for a prospective study of PDD 
in routine use, the other limitations of the RCTs should be 
addressed. We, therefore, planned this study to provide the 
first long-term prospective data comparing recurrence rates 
after routine PDD use vs. WL and to address the limita-
tions in the RCTs. We wanted to demonstrate: (1) Long-
term recurrence rates associated with routine use of PDD 
(we have previously demonstrated the benefit of PDD for 
3-month recurrence rates in the real-life setting [17]). (2) 
Long-term recurrence rates with PDD and WL, where only 
new tumours are included and (3) a comparison between 
PDD and WL where the quality of the initial resection can 
be controlled for and mitomycin C is given to all patients.
Therefore, the aim of this study was to compare total and 
risk group-specific recurrence rates in “good quality” (GQ) 
PDD-TURBT and “good quality” WL-TURBT when PDD is 
used in routine practice for all new NMIBC across a service.
Patients and methods
In 2006, based on national guidelines [18], it was planned 
that  Hexvix® PDD would be introduced for all new bladder 
tumour resections in the coming years. In anticipation of 
this, we planned a prospective study to collect data on all 
(consecutive patients) new tumour WL resections performed 
in 2007/2008 (the baseline control data) and continue once 
PDD was introduced for all new tumour resections in 
2009/2010. The attainment of quality indicators, along with 
all other study data was prospectively documented on the 
dedicated study proforma (Figure S1). The quality criteria 
that were aimed for and documented were: (1) resection 
done on lists by or with close supervision of the consultant; 
(2) a standardized proforma with cystoscopic bladder map-
ping used; (3) TURBT performed with the aim to completely 
resect all visible tumour and attainment of this documented; 
and (4) detrusor muscle was to be obtained and histologi-
cally confirmed. Patients were only included in the analysis 
if they had a first TURBT for new NMIBC and all the above 
quality criteria were met.
All patients received Mitomycin C within 24  h of 
TURBT, unless contraindicated. Risk stratification was 
based on 2002 EAU definitions to facilitate compari-
son with our series of studies [14, 15, 17]. All patients 
were discussed by cancer multi-disciplinary team that 
followed local criteria for chemo/immunotherapy usage, 
criteria for which did not change over the study. It was 
local policy that only patients with CIS or multi-focal G3 
would receive immediate BCG therapy (provided an early 
re-TURBT did not demonstrate MIBC). For all others, 
BCG was deferred until detection of residual disease at 
re-TURBT or until high-grade recurrence. All high-risk 
patients had early re-TURBT unless the risks outweighed 
the benefits. All other patients followed standard cysto-
scopic surveillance. WL resections were performed on the 
lists of six experienced consultants and PDD resections on 
lists of two consultants. Throughout the study period, all 
TURBT pathology specimens were assessed by the same 
two specialist, senior uro-pathologists using standardized 
reporting criteria.
The primary end point was the recurrence rate at 3 years 
(RR-3y). Recurrence was defined as histologically proven 
tumour occurring any time after first (deemed to be com-
plete) TURBT including at re-TURBT.
Rate of progression to MIBC and any grade and/or 
stage progression compared with initial resection was also 
examined.
To further control for confounder, patients were matched 
one to one on demographic and pathological criteria. Finally, 
logistical and Cox regression were performed to determine 
if observed differences were independent of the surgeon per-
forming the resection.
Patients were excluded from end point analysis (censored) 
if they had not had a documented recurrence and were lost 
to follow-up, died or became palliative or unfit.
Mean recurrence-free duration was assessed by 
Kaplan–Meir analysis and log-rank test. Snapshot recur-
rence and progression rates were compared by Chi-squared 
test and matched pair analysis by McNemar’s test. Medians 
(25th, 75th) were compared by Mann–Whitney U test. Sta-
tistical analysis was performed using SPSS v21.
Results
Of 808 patients screened for inclusion, 554/808 (68.5%) 
had NMIBC, 345/554 (62.3%) of whom had confirmed 
“good quality” resections and were included (Table 1). 
After censoring of patients who had not had a documented 
recurrence and who did not achieve 3 years of follow-up, 
135/153 (88.2%) WL and 146/192 (76.0%) PDD patients 
were assessed for recurrence at 3 years (Figure S2).
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Recurrence rates
The recurrence rate at 1 year (RR-1y) and RR-3y were 
significantly less with PDD than WL overall (Table 2A). 
There was significantly longer mean recurrence-free survival 
with PDD than WL [PDD: 52.9 (48.4–57.4) vs. WL: 42.4 
(36.7–48.1) months p = 0.001] (Fig. 1a). There was no sig-
nificant difference in median time to first recurrence [PDD: 
8.7 (3, 21) vs. WL: 5.9 (3, 14.0) months p = 0.17]. 
Binary logistical regression and Cox regression were per-
formed to determine if the benefit of PDD was independent 
of the surgeon performing the resection. Surgeon A and B 
performed 89% of all resections and were compared with 
the four other surgeons grouped. PDD was associated with 
significantly reduced recurrence rates at 3 years and sig-
nificantly better recurrence-free survival independent of 
surgeon [multivariate Cox HR for PDD vs. WL adjusted for 
surgeon = 0.57 (0.39–0.83) p = 0.003] (Table 3). Consider-
ing only the two higher volume surgeons, recurrence rate at 
3 years was still significantly less with PDD vs. WL [57/146 
(39.0) vs. 52/97 (53.0) OR 0.55 (0.33–0.93) p = 0.02]. Since 
there was more multi-focal, intermediate and high-risk dis-
ease identified in the PDD group, this adjusted regression in 
favour of PDD and thus multi-focality and risk group were 
not included as variables in the regression analysis.
Matched pair analysis
Subjects from WL and PDD groups were matched 1:1 
based on age (±10 years), grade (exact), stage (exact), risk 
group (exact) and follow-up time (<6 months, 6 months to 
1 year, >1–3 years and ≥3 years). 236/345 (68.4%) patients 
were successfully matched into 118 pairs. Matched recur-
rence rate was significantly less for PDD than WL overall 
(Table 2B).
Risk groups
The PDD group was significantly less likely to have unifo-
cal disease declared, significantly more likely to have >3 
tumours identified and significantly less likely to have low-
risk disease (Table 1).
RR-1y was significantly less in low- and high-risk groups 
with trend to significance in intermediate risk (Table 2A). 
This difference in snapshot recurrence was only maintained 
at 3 years in the high-risk group (Table 2A). Recurrence-
free survival was significantly better in low- and high-risk 
subgroups (Fig. 1b–d) with trend to significance in interme-
diate risk. In the matched pair analysis, PDD was associated 
with significantly reduced RR in intermediate and high-risk 
patients (Table 2B).
Table 1  Study population 
break down
a Local guidelines for BCG therapy were followed and did not change through the study, these stipulated 
that BCG would only be given immediately after first TURBT if there was CIS or multifocal G3, otherwise 
BCG could be deferred until detection of recurrent or residual high-grade disease
All patients
WL-TURBT PDD-TURBT p value
Screened 438 370
Median age (25, 75) 71.9 (64.4–80.1) 72.1 (62.2–79.8) 0.30
NMIBC at first TURBT 296 (66.8) 258 (69.7) 0.51
Good quality TURBT for NMIBC (included) 153/296 (51.7) 192/258 (74.4) <0.001
Risk groups
 Low (G1/G2 Ta, single and <3 cm) 65 (43.0) 57 (29.7) 0.01
 Intermediate (G1/G2, Ta/T1, ≥3 cm or multiple 
and <3 cm)
45 (29.8) 71 (37.0) 0.14
 High (high risk: G3, Ta/T1 including cis) 41 (27.2) 64 (33.3) 0.19
 CIS at first resection 6/153 (3.9) 10/192 (5.2) 0.57
 T1 27/153 (17.6) 45/192 (23.4) 0.19
 Unifocal 113/153 (73.9) 98/192 (51.0) <0.001
 >3 tumours 12/157 (7.8) 59/192 (30.7) <0.001
 Re-TURBT in high-risk patients 34/41 (82.9) 55/64 (85.9) 0.95
 Primary BCG in high-risk  patientsa 11/41 (26.8) 13/64 (20.3) 0.45
Follow-up
 Median follow-up (25, 75) 53.0 (19.9–65.5) 36.6 (22.3–43.2) <0.001
 Completed 3-year follow-up 105/153 (68.6) 127/192 (66.1) 0.65
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Progression
There was less new high-grade disease or MIBC discovered 
later in initially low/intermediate-risk disease with PDD 
compared with WL [PDD: 8/146 (5.5%) vs. WL: 18/135 
(13.3%) OR 0.38 (0.16–0.90) p = 0.03]. The progression 
rate to MIBC was 9/135 (6.7%) for WL and 9/146 (6.2%) 
for PDD. MIBC was found at a median of 19.4 (9.2–27.0) 
months follow-up.
Discussion
This study is unique and adds significant data to the cur-
rent literature. It is the only prospective controlled study, to 
our knowledge, that examines NMIBC recurrence rates with 
routine PDD use.
This study benefits from high-quality prospective data 
collection and the ability to compare resections that are 
matched for “quality criteria” providing control of confound-
ers potentially inherent in the non-randomised design.
The question of long-term impact of PDD on recur-
rence rates, particularly in high-risk patients has remained 
unanswered for some time [19]. PDD is considered as a tool 
which improves operative quality. Operative quality theoreti-
cally impacts short-term recurrence. In this study (despite 
otherwise identical operative quality), in high-risk GQ-PDD, 
48% went 3 years with no recurrence compared with 20% of 
high-risk GQ-WL.
These findings are at odds with the only other large long-
term study of patients receiving HAL-PDD where no differ-
ence was shown between WL and PDD. The crucial differ-
ence between that study and this is that 60% of patients in 
that study were recurrent bladder cancers (average bladder 
cancer history of 4.4–5 years) [2, 3]. It is possible that the 
impact of PDD on long-term recurrence rates is only pos-
sible if applied at first presentation. Then a truly complete 
resection identifying all tumours followed by Mitomycin C 
installation—may result in durable recurrence-free rates. 
This hypothesis is supported by the significantly greater 
number of tumours identified in the PDD group here. 
Although only documented, fully mapped and fully resected 
disease was included in this study, it is likely that there were 
more unseen tumours in the WL group resulting in higher 
recurrence rate. In contrast to other studies [7, 20], our data 
does not suggest that additional PDD-identified tumours 
Table 2  Recurrence rates with GQWL-TURBT vs. GQPDD-TURBT
A. 1- and 3-year recurrence rates in all study patients (excluding those who were censored before the end point). B. Individual subject matched-
pair analysis of 3-year recurrence rates overall and stratified by risk group. *  McNemar’s paired test. Subjects matched on age (±10  years), 
tumour grade (exact), tumour stage (exact), EAU 2002 risk group (which provides relevant matching for multifocality and tumour size) (exact), 
length of follow-up (<6 months, 6 months to 1 year, 1–3 years and ≥3 years). 72% of patients in the matched pair analysis had ≥3 years follow-
up, 89.8% had >1 year follow-up all had at least one check cystoscopy
A. All patients
1 year 3 years
RR-1y (%) OR (95% CI) p value RR-3y (%) OR (95% CI) p value
GQ-WL 56/144 (38.9) 0.43 (0.26–0.71) <0.001 72/135 (53.3) 0.56 (0.35–0.90) 0.02
GQ-PDD 37/172 (21.5) 57/146 (39.0)
Low risk
 GQ-WL 15/58 (25.9) 0.11 (0.02–0.54) 0.006 20/56 (35.7) 0.48 (0.19–1.19) 0.11
 GQ-PDD 2/51 (3.9) 9/43 (20.9)
Intermediate risk
 GQ-WL 18/44 (40.9) 0.48 (0.21–1.09) 0.08 23/42 (54.8) 0.61 (0.27–1.38) 0.24
 GQ-PDD 16/64 (25.0) 23/54 (42.6)
High risk
 GQ-WL 24/39 (61.5) 0.34 (0.15–0.79) 0.01 28/35 (80.0) 0.27 (0.10–0.74) 0.01
 GQ-PDD 20/57 (35.1) 25/48 (52.1)
B. Individual subject-matched pair analysis recurrence rate at last follow-up
RR-3y WL (%) PDD (%) OR (95% CI) p value*
All 59/118 (50.0) 29/118 (24.6) 0.33 (0.19–0.57) <0.001
Low 14/47 (29.8) 7/47 (14.9) 0.41 (0.15–1.14) 0.14
Intermediate 23/39 (59.0) 10/39 (25.6) 0.24 (0.09–0.63) 0.006
High 22/32 (68.8) 12/32 (37.5) 0.27 (0.10–0.77) 0.02
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were CIS (no significant difference in CIS rates in WL vs. 
PDD). The reason for this is not clear but may be due to the 
select “good quality” resection population included in this 
study and relatively low CIS rates.
We accept that we do not offer within-patient analy-
sis of findings with and without PDD. However, we feel 
that the difference in multifocality between WL and PDD 
is unlikely to be due to a true difference in multifocality 
but rather due to increased tumour detection by PDD. 
Increased tumour detection and correct staging may result 
in more appropriate subsequent management at the time 
of the index TURBT [21]. The difference in multifocality 
between the groups is thus not a confounder but a benefit 
of PDD and identification of this difference is a benefit of 
the study design (which may not be possible in the trial 
setting).
Time 0 12 24 36 48
GQ-
WL
Events 0 15 19 20 20
N at risk 65 43 38 36 30
GQ-
PDD
Events 0 2 8 9 9
N at risk 57 49 41 35 11
Time 0 12 24 36 48
GQ-
WL
Events 0 56 55 72 72
N at risk 153 88 67 63 50
GQ-
PDD
Events 0 37 49 57 57
N at risk 192 135 104 86 17
Time 0 12 24 36 48
GQ-
WL
Events 0 18 22 23 23
N at risk 45 26 21 19 18
GQ-
PDD
Events 0 16 22 23 23
N at risk 71 48 37 31 12
Time 0 12 24 36 48
GQ-
WL
Events 0 24 27 28 28
N at risk 41 15 11 7 5
GQ-
PDD
Events 0 20 23 25 25
N at risk 64 37 29 23 8
p=0.001 p=0.04
p=0.06 p=0.002
a b
c d
Fig. 1  a Kaplan–Meir graphs of recurrence-free survival in all patients for GQWL vs. GQPDD (p = 0.001, log-rank test). b–d Kaplan–Meir 
graphs of recurrence-free survival stratified by risk group
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Due to local BCG policy (“Patients and methods” sec-
tion), our BCG usage appears low [22] but our overall BCG 
rates (after residual disease or recurrence) are higher (not 
reported). Only the immediate pre-recurrence BCG reported 
is relevant to the outcome of this study (recurrence rate). 
Furthermore, both cohorts were managed with identical 
policy for BCG instillations.
We accept that this is not a randomized trial. We cannot 
conclusively determine PDD per-se resulted in the improve-
ments observed. It is possible that PDD acted as a learning 
tool—this itself may be a benefit. We also accept that the 
sequential temporal nature of these two cohorts is a limita-
tion to our study. We went to great lengths to control for 
this: sequential patients from each cohort were all included, 
patients from each cohort that received the highest possi-
ble standard of resection could be identified and compared, 
and further matched one to one based on demographic, risk 
group, and pathological criteria.
Finally, to be able to recommend routine adoption of PDD 
for all new tumours, cost–benefit analysis will be required.
Conclusion
The adoption of PDD for all new bladder tumour resections 
in routine practice appears to be associated with significantly 
reduced recurrence rates at 3 years in our “real-life” experi-
ence, particularly in high-risk disease.
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